ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the appointment of Charles Morris, MB, ChB, MRCP as Executive Vice President and Chief Development Officer, effective today. Dr. Morris will be responsible for leading all aspects of product development, including regulatory, at ImmunoGen. He reports to Daniel Junius, President and Chief Executive Officer.